Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2017-01-20 AGM Information
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Notice of extraordinary general meeting
AGM Information Classification · 98% confidence The document is explicitly titled 'REGISTRATION FORM – Extraordinary general meeting of Gentian Diagnostics AS' and contains instructions and fields for shareholders to register their attendance and voting intentions for an upcoming extraordinary general meeting (EGM) scheduled for 30 January 2017. This material is directly related to the logistics and administration of a shareholder meeting, which falls under the scope of AGM Information (AGM-R), even though it is for an EGM rather than a standard AGM, as it pertains to meeting participation materials.
2017-01-20 English
Notice of extraordinary general meeting
Proxy Solicitation & Information Statement Classification · 99% confidence The document is titled 'PROXY – Extraordinary general meeting of Gentian Diagnostics AS' and contains instructions for shareholders to authorize a proxy holder to vote on their behalf at a specific meeting date (30 January 2017). This material is explicitly designed to solicit shareholder votes and provide information related to voting at a general meeting. This aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). The document is short and directly related to the voting process for a meeting, not the meeting minutes (AGM-R) or the results (DVA).
2017-01-20 English
Notice of extraordinary general meeting
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Notice of extraordinary general meeting" and refers to enclosing the notice for this meeting. An Extraordinary General Meeting (EGM) is a type of shareholder meeting, similar to an AGM. Since there is no specific code for EGM notices, and the content relates to calling a meeting for shareholder decisions, it aligns most closely with the context of shareholder meetings. The closest available codes are AGM-R (AGM Information) or potentially PSI (Proxy Solicitation & Information Statement) if it contained detailed voting materials. However, a 'Notice' of a meeting, especially an extraordinary one, is often a precursor or related document to the AGM/EGM process. Given the options, AGM-R covers general meeting information, and this is a notice for a general meeting. Since it is a notice/announcement about a meeting, and not the voting results (DVA) or proxy materials (PSI), AGM-R is the most appropriate fit among the provided choices for general meeting documentation.
2017-01-20 English
Mandatory notification of trade of primary insider
Director's Dealing Classification · 100% confidence The document is explicitly titled "Mandatory notification of trade of primary insider" and details share transactions (acquisitions) made by the Chief Financial Officer, Chairman of the Board, and other Board members in connection with a private placement. This directly corresponds to the definition of Director's Dealing (insider trades). Filing Category: DIRS (Director's Dealing).
2017-01-20 English
PRIVATE PLACEMENT - BOOKBUILDING IN TRANCHE 1 SUCCESSFULLY COMPLETED - APPLICATION PERIOD IN TRANCHE 2 COMMENCES TODAY
Share Issue/Capital Change Classification · 99% confidence The document explicitly discusses a 'PRIVATE PLACEMENT' involving the 'issuance of up to 2,857,143 new shares' and details the completion of Tranche 1 and the commencement of Tranche 2 bookbuilding/application period. This activity directly relates to raising capital through the issuance of new securities, which falls under the definition of Capital/Financing Update (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general regulatory announcement (RNS), as it details a specific financing event.
2017-01-20 English
GENTIAN DIAGNOSTICS - CONTEMPLATED PRIVATE PLACEMENT
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a 'CONTEMPLATED PRIVATE PLACEMENT' of up to NOK 100 million in new shares. This involves fundraising, setting an offer price (NOK 35 per share), defining tranches for investors, and mentioning the need for corporate resolutions and shareholder approval (implying a future general meeting). This activity directly relates to raising capital and changing the capital structure. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full 10-K, an ER, or a simple DIV announcement; it is a specific financing event.
2017-01-19 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.